Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

E&C investigation

This article was originally published in The Tan Sheet

Executive Summary

The House Energy and Commerce Subcommittee on Oversight and Investigations announces Aug. 24 it is investigating FDA's plan to outsource jobs. Energy and Commerce Chairman John Dingell, D-Mich., and Subcommittee Chair Bart Stupak, D-Mich., say in a release they were "incredulous" when they learned of FDA's plan to outsource 332 positions. The news comes one week after Dingell and Stupak commended the Office of Regulatory Affairs' plan to shut down seven labs (1"The Tan Sheet" Aug. 27, 2007, p. 6). The congressmen are asking for a list of the positions as well as descriptions of job responsibilities, records reflecting the plans, budget analyses and more by Sept. 7...

You may also be interested in...



ORA Lab Closings Cancelled But Reorganization Not Off The Table – Staffers

FDA's head of regulatory affairs' Aug. 17 message to staff about cancelling plans to close seven field labs did not mark the end of the agency's ORA reorganization work, staff members say

Pandemic Puts A Spotlight On Counterfeit Drugs

As the ongoing COVID-19 pandemic forces health care to go digital, opportunities for fraud have proliferated. In Vivo explores the risks, the steps regulators are taking and how companies are looking to provide innovative solutions to help secure manufacturing supply chains.

Pharma-Biotech Licensing Trends To Watch For In 2021

More option deals, greater use of alternative remedy clauses and aggressive diligence of assets. Geoffrey Spolyar, special counsel at Cooley, spotlights some of the changes he is seeing in pharma and biotech partnership agreements and explains why these trends matter in 2021.

Topics

UsernamePublicRestriction

Register

PS100861

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel